Therapy News and Research

RSS

Novel oral anticoagulant bleeding risk offsets clinical benefit

The use of orally activated Xa antagonist and direct thrombin inhibitors is associated with a significant increase in major bleeding events in acute coronary syndrome patients, a study shows.

27 Sep 2012

Obesity affects taste in children, adolescents

Study results show that obese children perceive taste differently from their healthy weight peers, being significantly less able to identify the individual tastes of salty, umami, and bitter.

27 Sep 2012

Warfarin therapy should not be stopped completely after GI bleeding

The decision to not resume warfarin therapy following a gastrointestinal bleeding event is linked to an increased risk for thrombosis and mortality, researchers suggest.

27 Sep 2012

GW to evaluate effectiveness of glucose-lowering drugs against type 2 diabetes

John Lachin, professor of biostatistics, epidemiology and statistics at the George Washington University, has been awarded a five-year, $134 million grant from the National Institute of Health's National Institute of Diabetes and Digestive and Kidney Diseases to conduct a clinical trial examining the long-term effectiveness of several glucose-lowering medications for treatment of people with type 2 diabetes. The grant sets a record as the largest sum award GW has ever received.

27 Sep 2012

Scientists discover 12 genetic markers for ED in prostate cancer patients after radiotherapy

In the first study of its kind, a research team led by Mount Sinai School of Medicine and Albert Einstein College of Medicine of Yeshiva University discovered 12 genetic markers associated with the development of erectile dysfunction (ED) in prostate cancer patients who were treated with radiation.

27 Sep 2012

Pfizer, Bristol-Myers Squibb report FDA acknowledgement of ELIQUIS NDA resubmission

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the New Drug Application (NDA) resubmission for ELIQUIS (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF).

27 Sep 2012

Karolinska Institutet scientists discover new approach to treat type II diabetes

An international team of scientists, led from Karolinska Institutet in Sweden, have discovered an entirely new approach to the treatment of type II diabetes. The therapy involves the blockade of signalling by a protein known as VEGF-B and this prevents fat from accumulating in the 'wrong' places, such as in muscles and in the heart. As a result the cells within these tissues are once again able to respond to insulin.

27 Sep 2012

Loyola now offers sacral nerve stimulation for patients with fecal incontinence

Fecal incontinence, or the inability to control the bowels, is a highly underreported and stigmatized condition, according to colorectal surgeons at Loyola University Health System (LUHS).

27 Sep 2012

Accera to sponsor National Memory Screening Day of Alzheimer's Foundation of America

Accera, Inc., a privately-held, commercial-stage, healthcare company focused on the discovery and development of innovative clinical applications to address acute and chronic neurodegenerative diseases, announced today that it is a silver sponsor of the Alzheimer's Foundation of America's (AFA) National Memory Screening Day (NMSD) on November 13, 2012 during National Alzheimer's Disease Awareness Month.

27 Sep 2012

CeQur completes PaQ Insulin Delivery Device clinical study on type 2 diabetes

CeQur SA, a company focused on the development and commercialization of simple insulin delivery devices, announced the completion of a clinical study with the company's PaQ Insulin Delivery Device.

27 Sep 2012

Journal of Vascular and Interventional Radiology debuts new iPad app

As tablet ownership trends away from early adopters and moves to the mainstream, the Journal of Vascular and Interventional Radiology has debuted a new app, available for iPad users, that will allow readers to access interventional radiology literature and multimedia—when they choose, ensuring fast, convenient access to up-to-the-minute peer-reviewed articles, podcasts, images and more.

27 Sep 2012

Enrollment complete in Boehringer Ingelheim’s nintedanib phase III studies for IPF

Boehringer Ingelheim Pharmaceuticals, Inc. announced that clinical trial enrollment has completed for two phase III studies evaluating the safety and efficacy of nintedanib (BIBF 1120), an investigational compound, in patients with idiopathic pulmonary fibrosis (IPF), being studied at a twice-daily oral dose.

27 Sep 2012

CTCA at Midwestern named Certified Quality Breast Center of Excellence

Cancer Treatment Centers of America (CTCA) at Midwestern Regional Medical Center (Midwestern) has been recognized by the National Quality Measures for Breast Centers Program (NQMBC) as being among the top centers in the country for providing quality breast cancer care.

27 Sep 2012

Positive results from Sobi, Biogen Idec's rFIXFc Phase 3 trial on hemophilia B

Biogen Idec and Swedish Orphan Biovitrum (Sobi) today announced positive results from B-LONG, a clinical study that evaluated a new long-lasting clotting factor candidate in people with hemophilia B. Hemophilia B is a rare inherited disorder that impairs blood coagulation.

27 Sep 2012

Antibiotic therapy can effectively treat acute appendicitis

Although the standard approach to acute appendicitis is to remove the appendix, a study at the Sahlgrenska Academy, University of Gothenburg, Sweden, reveals that treatment with antibiotics can be just as effective in many cases.

27 Sep 2012

CSL develops new drug candidate against type 2 diabetes

CSL Limited has developed a new drug candidate that is able to prevent the development of type 2 diabetes and reverse its progression in animal models of the disease.

27 Sep 2012

Short-course amphotericin is cost-effective for cryptococcal meningitis

The treatment of cryptococcal meningitis in resource-limited settings is most effective with a short 1-week course of amphotericin induction therapy coupled with high-dose fluconazole for at least 2 weeks, a Ugandan study suggests.

26 Sep 2012

Tips on safe use of opioids in hospitals

On August 8, The Joint Commission issued a Sentinel Event Alert on the safe use of opioids in hospitals. The Alert discussed the significance of accurate pain assessment and effective pain management plans.

26 Sep 2012

NOXXON commences NOX-A12 Phase IIa trial in relapsed MM

NOXXON Pharma today announced the treatment of the first cohort of three multiple myeloma (MM) patients in a Phase IIa clinical trial of its anti-CXCL12/SDF-1 (CXC chemokine ligand 12 / Stromal Cell-Derived Factor-1) Spiegelmer NOX-A12.

26 Sep 2012

CivaTech Oncology receives NIH/NCI Phase II Contract for CivaSheet device to treat NSCLC

CivaTech Oncology, an RTP medical device company dedicated to developing novel radiation therapy devices, announced the award of a $1M Phase II Contract from the National Institutes of Health and the National Cancer Institute to further develop and commercialize CivaSheet, a bioabsorbable uni-directional device for treatment of non-small-cell lung cancer.

26 Sep 2012